Can someone explain to me what's wrong with Indevus (IDEV)? The company is selling for about 2X cash. It has a best-in-its-class drug approved, SANCTURA, for a 2 billion-dollar market. Sales seem to be going well. The pipeline is interesting and moving along well. Management seems solid. Yet the stock is now selling for less than the day its drug was approved by the FDA.
Market Data 
Markets 
AI
